Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Provided By PR Newswire

Last update: Nov 1, 2022

SBT-272 Phase 1 safety and tolerability data support further clinical development

SBT-272 was neuroprotective and reduced neuroinflammation in ALS preclinical model